Adnexus Files For $86M IPO; Funds For Adnectin Pipeline

On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products. (BioWorld Today)